Aldeyra Therapeutics: A Mispriced Gem With Reproxalaps CRL Creating A Golden Buying Opportunity
…
2,340€
0,21%
Echtzeit-Aktienkurs Aldeyra Therapeutics
Bid:
Ask:
Nachrichten zur Aldeyra Therapeutics Aktie
ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors may be able to Recover Losses in Class Action Investigation -- Contact BFA Law (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc. investors that lost money are encouraged to contact BFA Law about its ongoing securities investigation.…
Kirby McInerney LLP Announces Investigation of Possible Claims Against Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Investors
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential…
Aldeyra Therapeutics tanks as FDA rejects investigational dry eye disease therapy
Aldeyra Therapeutics (NASDAQ:ALDX) shares plummeted more than 70% after the biotechnology company received a letter of refusal from the Food…
Aldeyra Therapeutics Is Severely Undervalued Before PDUFA
…
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Investors need to pay close attention to Aldeyra Therapeutics (ALDX) stock based on the movements in the options market lately.…
Aldeyra Therapeutics Aktie: Umsatzprognosen klar übertroffen!
Die Aldeyra Therapeutics Aktie verzeichnete am 23. November einen bemerkenswerten Handelstag mit einem Kursanstieg von 1,73 Prozent auf 4,70 EUR.…
Aldeyra Therapeutics Aktie: Zusammenschluss bringt Erfolg!
Aldeyra Therapeutics, ein auf immunvermittelte Krankheiten spezialisiertes Biotechnologieunternehmen, verzeichnet eine bemerkenswerte Entwicklung an der Börse. Die Aktie konnte im vergangenen…
Aldeyra Therapeutics Aktie: Fortschritte in klinischen Studien
Die Aldeyra Therapeutics Aktie zeigt sich in jüngster Zeit stabil mit leichten Schwankungen. Am 25. Oktober 2024 notierte die Aktie…
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a…
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN,…
Heres Why You Should Invest in Aldeyra (ALDX) Stock Now
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent…
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a…